GeoVax Labs, Inc. (NASDAQ:GOVX) Q2 2023 Earnings Call Transcript

Again we’ll keep you updated as more data comes in and at the same thing as we progress with our MVA vaccine to become the first U.S.-based supplier of such a vaccine and help the world supply, et cetera. And then shook, of course, our manufacturing process improvement. So we’ll keep you updated. Our focus is on accelerating to these milestone catalysts. Our goal is to deliver critically needed vaccines and immunotherapies to build shareholder and stakeholder value while providing highly motivating career development opportunities for our team. We take that very seriously. We’ll to acknowledge and thank our Board of Directors, our staff and the many other parties who continue to support, advice, counsel and assist us as we move forward. So thank you for your interest.

Please circle back if you have further questions. We appreciate your time, attention and interest. Thank you. Have a good day.

Operator: This concludes today’s conference call. You may now disconnect.